| | First author, publication year, country | Sample size (% men) | Population age (years) | Time window from stroke onset to intervention (hours) | Intervention | Control | Efficacy outcomes | Safety outcomes | Time window from stroke onset to examination (days) | Baseline NIHSS |
| | Ladurner, 2005, Austria, Czech Republic, and Hungary | 146 (58.2) | 45–85 | 24 | Cerebrolysin for 21 days, 50 mL/d, IV | Placebo for 21 days | CNS, BI, GCS, CGI, MMSE, SST, HAMD | AE, SAE, lab tests, vital signs | 1, 3, 7, 14, 21, 90 | NA | | Jianu, 2010, Romania | 156 (71.8) | 20–75 | 72 | Cerebrolysin for 21 days, 30 mL/d, IV | Placebo for 21 days | mRS, mortality | AE | 90 | 14 | | Heiss, 2012, China, Hong Kong, Republic of Korea, and Myanmar | 1067 (60) | 18–85 | 12 | Cerebrolysin for 10 days, 30 mL/d, IV, in addition to aspirin (100 mg/d) | Placebo for 10 days in addition to aspirin (100 mg/d) | mRS, BI, NIHSS | AE, SAE, lab tests, vital signs | 90 | 9 | | Lang, 2013, Austria, Croatia, Czech Republic, Slovenia, and UK | 119 (64.7) | 18–80 | 3 | Cerebrolysin for 10 days, 30 mL/d, IV | Placebo for 10 days | mRS, NIHSS, BI, GOS | AE, SAE, lab tests, vital signs | 5, 10, 30, 90 | Active: 12.3 | | Control: 11 | | Amiri-Nikpour, 2014, Iran | 46 (51.2) | 18–85 | 12–30 | Cerebrolysin for 10 days, 30 mL/d, IV, adjunct to 100 mg of aspirin daily | Placebo for 10 days adjunct to 100 mg of aspirin daily | NIHSS, mean flow velocity (cm/s) of cerebral arteries, PI | NA | 30, 60, 90 | 14 | | Muresanu, 2016, Romania, Ukraine, and Poland | 205 (63.9) | 18–80 | 24–72 | Cerebrolysin for 21 days, 30 mL/d, IV | Placebo for 21 days | ARAT, NIHSS, BI, mRS | AE, SAE, lab tests, vital signs | 42, 90 | Active: 9.1 | | Control: 9.2 | | Xue, 2016, China | 40 (47.5) | 52–87 | 12 | Cerebrolysin for 10 days, 30 mL/d, IV | Placebo for 10 days | NIHSS, BI | Adverse events, lab tests, vital signs | 11 and 21 days after the initiation of therapy | Active: 10.6 | | Control: 10.2 |
|
|
AE, adverse event; ARAT, Action Research Arm Test; BI, Barthel Index; CGI, Clinical Global Impressions; CNS, Canadian Neurological Scale; GCS, Glasgow Coma Scale; GOS, Glasgow Outcome Scale; HAMD, Hamilton Rating Scale for Depression; IQR, interquartile range; MMSE, Mini-Mental State Examination; mRS, modified Rankin Scale; NA, not available; NIHSS, National Institutes of Health Stroke Scale; PI, pulsatility index; SAE, serious adverse event; SD, standard deviation; SST, syndrome short test; UNSS, Unified Neurological Stroke Scale.
|
